



Momenta Pharmaceuticals Announces Proposed Public Offering of Common Stock

December 5, 2018

CAMBRIDGE, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company with a validated scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases, today announced that it is commencing an underwritten registered public offering of \$150,000,000 of shares of its common stock. Momenta also expects to grant the underwriter of the offering an option to purchase up to an additional \$22,500,000 of shares of its common stock, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Momenta.

Goldman Sachs & Co. LLC is acting as sole book-running manager for the offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was initially filed with the U.S. Securities and Exchange Commission (SEC) on February 29, 2016. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by telephone at (866) 471-2526 or e-mail at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of shares of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Momenta

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta's lead product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hslgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta's wholly-owned proposed biosimilar to HUMIRA[®], and M710, a proposed biosimilar to EYLEA[®] being developed in collaboration with Mylan. Momenta's two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa[®] (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.

Momenta's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to the underwritten public offering, the timing of filing a preliminary prospectus supplement, the grant of an option to the underwriter, the Company's expectations on the timing, size and completion of the offering and market potential and product revenues of the Company's product candidates. Forward-looking statements may be identified by words and phrases such as "advance," "anticipate," "being developed," "believe," "continue," "expect," "guidance," "look forward to," "may," "plan," "possible," "potential," "progress," "propose," "remains," "target," "will," "working toward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Young Kwon
Momenta Pharmaceuticals
1-617-395-4964
IR@momentapharma.com

MEDIA CONTACT:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
[Momenta@macbiocom.com](mailto:momenta@macbiocom.com)



Source: Momenta Pharmaceuticals, Inc.